Updating results

260 results for eq-5d Sort: Relevance | Date

Percutaneous vertebroplasty and percutaneous balloon kyphoplasty for treating osteoporotic vertebral compression fractures (TA279)

Evidence-based recommendations on percutaneous vertebroplasty and percutaneous balloon kyphoplasty for osteoporotic vertebral compression fractures

Technology appraisal guidance Published April 2013

Neuropathic pain in adults: pharmacological management in non-specialist settings (CG173)

Evidence-based recommendations on the pharmacological management of neuropathic pain in adults in non-specialist settings

Clinical guideline Published November 2013 Last updated April 2018

Prucalopride for the treatment of chronic constipation in women (TA211)

Evidence-based recommendations on prucalopride (Resolor) for treating chronic constipation in women

Technology appraisal guidance Published December 2010

Tocilizumab for the treatment of rheumatoid arthritis (TA247)

Evidence-based recommendations on tocilizumab (RoActemra) for treating rheumatoid arthritis

Technology appraisal guidance Published February 2012

Eluxadoline for treating irritable bowel syndrome with diarrhoea (TA471)

Evidence-based recommendations on eluxadoline (Truberzi) for treating irritable bowel syndrome (IBS) with diarrhoea in adults

Technology appraisal guidance Published August 2017

Aflibercept for treating visual impairment caused by macular oedema secondary to central retinal vein occlusion (TA305)

Evidence-based recommendations on aflibercept (Eylea) for visual impairment caused by macular oedema secondary to central retinal vein occlusion

Technology appraisal guidance Published February 2014

Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma (TA396)

Evidence-based recommendations on trametinib (Mekinist) with dabrafenib (Tafinlar) for treating unresectable or metastatic melanoma with a BRAF V600 mutation

Technology appraisal guidance Published June 2016

Ranibizumab for treating choroidal neovascularisation associated with pathological myopia (TA298)

Evidence-based recommendations on ranibizumab (Lucentis) for treating choroidal neovascularisation associated with pathological myopia

Technology appraisal guidance Published November 2013

Osimertinib for treating locally advanced or metastatic EGFR T790M mutation-positive non-small-cell lung cancer (TA416)

Evidence-based recommendations on osimertinib (Tagresso) for treating locally advanced or metastatic EGFR T790M mutation-positive non-small-cell lung cancer

Technology appraisal guidance Published October 2016

Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor (TA195)

Evidence-based recommendations on adalimumab, etanercept, infliximab, rituximab and abatacept for treating rheumatoid arthritis after failure of a TNF inhibitor

Technology appraisal guidance Published August 2010

Mirabegron for treating symptoms of overactive bladder (TA290)

Evidence-based recommendations on mirabegron (Betmiga) for treating the symptoms of overactive bladder

Technology appraisal guidance Published June 2013

Ustekinumab for the treatment of adults with moderate to severe psoriasis (TA180)

Evidence-based recommendations on ustekinumab (Stelara) for treating moderate to severe psoriasis in adults

Technology appraisal guidance Published September 2009 Last updated March 2017

Abiraterone for castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen (TA259)

Evidence-based recommendations on abiraterone (Zytiga) for castration-resistant metastatic prostate cancer in adults previously treated with docetaxel

Technology appraisal guidance Published June 2012 Last updated July 2016

Topotecan for the treatment of relapsed small-cell lung cancer (TA184)

Evidence-based recommendations on topotecan (Hycamtin) for treating relapsed small-cell lung cancer (SCLC)

Technology appraisal guidance Published November 2009

Regorafenib for previously treated advanced hepatocellular carcinoma (TA514)

Evidence-based recommendations on regorafenib (Stivarga) for previously treated advanced hepatocellular carcinoma (liver cancer) in adults

Technology appraisal guidance Published March 2018

Palbociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer (TA495)

Evidence-based recommendations on palbociclib (Ibrance) as initial endocrine-based therapy for hormone receptor-positive, HER2-negative, locally advanced or

Technology appraisal guidance Published December 2017

Omalizumab for treating severe persistent allergic asthma (TA278)

Evidence-based recommendations on omalizumab (Xolair) for treating severe persistent allergic asthma

Technology appraisal guidance Published April 2013

Lumacaftor–ivacaftor for treating cystic fibrosis homozygous for the F508del mutation (TA398)

Evidence-based recommendations on lumacaftor–ivacaftor (Orkambi) for treating cystic fibrosis in people 12 years and older who are homozygous for the F508del..

Technology appraisal guidance Published July 2016

Romiplostim for the treatment of chronic immune (idiopathic) thrombocytopenic purpura (TA221)

Evidence-based recommendations on romiplostim (Nplate) for treating chronic immune (idiopathic) thrombocytopenic purpura (ITP)

Technology appraisal guidance Published April 2011 Last updated May 2014

Bisphosphonates for treating osteoporosis (TA464)

Evidence-based recommendations on bisphosphonates (alendronic acid; ibandronic acid; risedronate sodium; zoledronic acid) for treating osteoporosis in adults

Technology appraisal guidance Published August 2017 Last updated February 2018

Denosumab for the prevention of osteoporotic fractures in postmenopausal women (TA204)

Evidence-based recommendations on denosumab (Prolia) for preventing osteoporotic fragility fractures in postmenopausal women

Technology appraisal guidance Published October 2010

Nivolumab for previously treated squamous non-small-cell lung cancer (TA483)

Evidence-based recommendations on nivolumab (Opdivo) for locally advanced or metastatic squamous non-small-cell lung cancer (NSCLC) in adults after chemotherapy

Technology appraisal guidance Published November 2017

Apremilast for treating moderate to severe plaque psoriasis (TA419)

Evidence-based recommendations on apremilast (Otezla) for treating moderate to severe plaque psoriasis in adults

Technology appraisal guidance Published November 2016

Enzalutamide for metastatic hormone‑relapsed prostate cancer previously treated with a docetaxel‑containing regimen (TA316)

Evidence-based recommendations on enzalutamide (Xtandi) for metastatic hormone-relapsed prostate cancer previously treated with a docetaxel-containing regimen

Technology appraisal guidance Published July 2014

Baricitinib for moderate to severe rheumatoid arthritis (TA466)

Evidence-based recommendations on baricitinib (Olumiant) for moderate to severe rheumatoid arthritis in adults

Technology appraisal guidance Published August 2017

Abiraterone for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated (TA387)

Evidence-based recommendations on abiraterone (Zytiga) for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated in adults.

Technology appraisal guidance Published April 2016 Last updated July 2016

Vedolizumab for treating moderately to severely active Crohn's disease after prior therapy (TA352)

Evidence-based recommendations on vedolizumab (Entyvio) for moderately to severely active Crohn's disease if TNF-alpha therapy has not worked or...

Technology appraisal guidance Published August 2015

Sacubitril valsartan for treating symptomatic chronic heart failure with reduced ejection fraction (TA388)

Evidence-based recommendations on sacubitril valsartan (Entresto) for treating symptomatic chronic heart failure with reduced ejection fraction

Technology appraisal guidance Published April 2016

Brodalumab for treating moderate to severe plaque psoriasis (TA511)

Evidence-based recommendations on brodalumab (Kyntheum) for treating moderate to severe plaque psoriasis in adults

Technology appraisal guidance Published March 2018

Adalimumab for treating moderate to severe hidradenitis suppurativa (TA392)

Evidence-based recommendations on adalimumab (Humira) for treating moderate to severe hidradenitis suppurativa (HS) (acne inversa)

Technology appraisal guidance Published June 2016

Pazopanib for the first-line treatment of advanced renal cell carcinoma (TA215)

Evidence-based recommendations on pazopanib (Votrient) for the first-line treatment of advanced renal cell carcinoma (RCC/kidney cancer)

Technology appraisal guidance Published February 2011 Last updated August 2013

Regorafenib for previously treated unresectable or metastatic gastrointestinal stromal tumours (TA488)

Evidence-based recommendations on on regorafenib (Stivarga) for previously treated gastrointestinal stromal tumours in adults

Technology appraisal guidance Published November 2017

Avelumab for treating metastatic Merkel cell carcinoma (TA517)

Evidence-based recommendations on avelumab (Bavencio) for treating metastatic (secondary) Merkel cell carcinoma (skin cancer) in adults

Technology appraisal guidance Published April 2018

Pemetrexed maintenance treatment for non-squamous non-small-cell lung cancer after pemetrexed and cisplatin (TA402)

Evidence-based recommendations on pemetrexed (Alimta) for locally advanced or metastatic non-squamous non-small-cell lung cancer in adults who have had..

Technology appraisal guidance Published August 2016

Ramucirumab for previously treated locally advanced or metastatic non-small-cell lung cancer (TA403)

Evidence-based recommendations on ramucirumab (Cyramza) for treating previously treated locally advanced or metastatic non-small-cell lung cancer

Technology appraisal guidance Published August 2016

Mepolizumab for treating severe refractory eosinophilic asthma (TA431)

Evidence-based recommendations on mepolizumab (Nucala) for treating severe refractory eosinophilic asthma in adults

Technology appraisal guidance Published January 2017

Obinutuzumab in combination with chlorambucil for untreated chronic lymphocytic leukaemia (TA343)

Evidence-based recommendations on obinutuzumab (Gazyvaro) with chlorambucil for treating untreated chronic lymphocytic leukaemia

Technology appraisal guidance Published June 2015

Intramuscular diaphragm stimulation for ventilator-dependent chronic respiratory failure caused by motor neurone disease (IPG593)

Evidence-based recommendations on intramuscular diaphragm stimulation for ventilator-dependent chronic respiratory failure in people with motor neurone disease

Interventional procedures guidance Published September 2017

Infliximab for the treatment of adults with psoriasis (TA134)

Evidence-based recommendations on infliximab (Remicade) for treating psoriasis in adults

Technology appraisal guidance Published January 2008

Nivolumab for previously treated non-squamous non-small-cell lung cancer (TA484)

Evidence-based recommendations on nivolumab (Opdivo) for locally advanced or metastatic (secondary) non-squamous non-small-cell lung cancer in adults after

Technology appraisal guidance Published November 2017